The ESMO position paper on biosimilars in oncology: Enhancing the provision of accurate education and information

ESMO Open

Volumn 2, Issue 3, 2017, Pages

  Schiestl, Martin ^a   Krendyukov, Andriy ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Sandoz Pharma Ltd   (Switzerland)

Author keywords

biosimilars; extrapolation; filgrastim; oncology; switching

Indexed keywords

EID: 85039763645     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2017-000245     Document Type: Editorial

References (11)

1. Tabernero J, Vyas M, Giuliani R, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open 2017;1:e000142.
2. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products), 2012. http://www. ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2009/12/WC500020062. pdf (accessed 27 Jun 2017).
3. European Medicines Agency. Guideline on similar biological medicinal products, 2015. http://www.ema.europa.eu/docs/en-GB/document-library/Scientifc-guideline/2014/10/WC500176768.pdf (accessed 27 Jun 2017).
4. European Medicines Agency/European Commission. Biosimilars in the EU. Information for healthcare professionals, 2017. http://www. ema.europa.eu/docs/en-GB/document-library/Leafet/2017/05/WC500226648. pdf (accessed 27 Jun 2017).
5. European Medicines Agency. Guideline on similar biological medicinal productscontaining biotechnology-derived proteins as activesubstance: non-clinical and clinical issues. http://www. ema. europa.eu/docs/en-GB/document-library/Scientifc-guideline/2015/01/WC500180219.pdf.
6. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood 2012;120:5111-7.
7. Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood 2014;124:3191-6.
8. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther 2012;91:405-17.
9. ICH. Q5E guideline on 'Comparability of biotechnological/biological products subject to changes in their manufacturing process', 2004. http://www.ich.org/fleadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/Q5E/Step4/Q5E-Guideline.pdf (accessed 28 Jun 2017).
10. Kurki P, van Aerts L, Wolff-Holz E, et al. Interchangeability of Biosimilars: A European Perspective. BioDrugs 2017;31:83-91.
11. Gascon P, Krendyukov A, Höbel N, et al. Treatment patterns and outcomes in the DLBCL cohort of a study (MONITOR-GCSF) assessing biosimilar flgrastim for prophylaxis of chemotherapy-induced/febrile neutropenia. Hematol Oncol 2017;35:351.